Dr. Nozha Boujemaa will oversee the company scientific vision as well as strategies for innovation, development and academic and industrial partnerships for iBiopsy®, the Median Technologies Imaging Phenomics platform.
Read moreMedian Technologies reports its financial results for H1 2018 and announces its strategic shift in focus to its imaging phenomics platform iBiopsy®
H1 2018 revenue: €3.4 million
Order backlog as of June 30, 2018: €21.4 million
Refocusing research and development activities on iBiopsy®
Median Technologies, The Imaging Phenomics Company®, announces that on July 11, it received the 2018 Futur40 award and special recognition prize in the category “Health-Life Sciences”. These prizes are awarded by Forbes, PMEFinance-EuropeEntrepreneurs and their partners Euronext, MorningStar, RSM, F2iC and Paris Europlace to distinguish French champions of growth.
Read moreMedian Technologies will share and showcase its offering for imaging solutions and services in clinical trials, featuring iSee®, their next generation image analysis and management platform, and ImageBank™, their latest solution for Phase I Cancer Centers, at booth #6106.
Read moreTo download this content please complete the form below
[contact-form-7 id="5108" title="Download file form"]